Nasus Pharma Ltd. · 2.8/10 — Weak · Updated September 2026
Last updated: September 2026
Factor Snapshot
Invetso Quality Score
2.8 (Weak)
Core Drivers
No durable economic engine is visible: The company shows no evidence of protected pricing power, sticky customer economics, or other durable advantages that would support long-term compounding versus global peers.
Capital is not compounding efficiently: Deeply negative returns on capital dominate the profile and indicate that incremental resources have not been translating into value creation, which is the most important long-term weakness.
Balance-sheet risk is contained but not enough to offset weak fundamentals: Liquidity and modest leverage reduce near-term distress risk, but they do not change the fact that the business lacks a proven self-funding growth model.
Peer positioning is lagging: Relative to stronger global peers, NSRX sits behind on durability, scale economics, and reinvestment quality, leaving it with a materially weaker long-term investment profile.
Key Constraints
Negative capital returns cap upside: The most decisive constraint is the inability to generate acceptable returns on invested capital, which limits the odds that growth or reinvestment will compound into durable shareholder value.
Growth visibility is thin: There is little evidence of a repeatable growth engine, scalable demand base, or operating leverage, so future expansion remains uncertain and dependent on execution improvement.
Financial flexibility is only partial protection: A relatively strong liquidity position helps absorb shocks, but leverage and weak cash-generation visibility still leave the company more exposed than higher-quality peers.
Synthesis
NSRX’s investment profile is defined more by what is missing than by what is proven. The company does not show a durable moat, a convincing scaling mechanism, or evidence that capital is being deployed at attractive returns, and those weaknesses dominate the assessment. Its balance sheet is not the main problem, since liquidity and leverage are manageable, but that only limits downside rather than creating a strong long-term compounding case. Relative to global peers, it is clearly lagging on the factors that matter most for sustained investment quality: durability, capital efficiency, and scalable growth. The result is a profile with constrained upside and only partial downside protection, which keeps the overall quality firmly in weak territory.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Nasus Pharma Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

